Prosecution Insights
Prosecution Insights
← Back to Regeneron Pharmaceuticals Inc.
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19333578 | DEVICES AND METHODS FOR OVERFILLING DRUG CONTAINERS | SHRIEVES, STEPHANIE ALEXANDRA | 3753 | DP | Non-Final OA | — | Pending | Sep 19, 2025 |
| 19333264 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §103 | Non-Final OA | 43d | Pending | Sep 18, 2025 |
| 19248893 | METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREBY | KIM, YUNSOO | 1641 | §112DP | Non-Final OA | 8d | Pending | Jun 25, 2025 |
| 19057507 | MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS | BALL, JOHN C | 1795 | §103§112Other | Non-Final OA | — | Pending | Feb 19, 2025 |
| 19024513 | VEGF-TRAP PROTEIN VARIANTS AND ANALYSIS THEREOF | SUN, CAITLYN MINGYUN | 1795 | §103 | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18999448 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112DP | Non-Final OA | — | Pending | Dec 23, 2024 |
| 18945863 | SYSTEMS AND METHODS FOR PRODUCING SMALL-SCALE MIXERS FOR DRUG MANUFACTURING | PATEL, VISHAL I | 1746 | §103 | Non-Final OA | — | Pending | Nov 13, 2024 |
| 18942224 | ASPARAGINE FEED STRATEGIES TO IMPROVE CELL CULTURE PERFORMANCE AND MITIGATE ASPARAGINE SEQUENCE VARIANTS | SINGH, SATYENDRA K | 1657 | §103 | Non-Final OA | — | Pending | Nov 08, 2024 |
| 18918283 | RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL | KNIGHT, TERESA E | 1634 | §102§103 | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18884527 | Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) Inhibitors | MEYERING, SHABANA SHABBEER | 1635 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18830643 | ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF | BOESEN, AGNIESZKA | 1672 | §112 | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18798198 | Treatment Of Hyperglycemia With Solute Carrier Family 39 Member 5 (SLC39A5) Inhibitors | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18786335 | METHODOLOGY TO CHARACTERIZE EMPTY-FULL RATIO IN CRUDE AAV SAMPLES | GILL, RACHEL B | 1671 | §102§103§112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18785975 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | RICCI, CRAIG D | 1611 | §102§112Other | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18777757 | SYSTEMS AND METHODS FOR MOTOR ASSESSMENT | EDWARDS, ETHAN WESLEY | 2857 | §101§103 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18776820 | METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST | HOWARD, ZACHARY C | 1674 | Other | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18763490 | METHODS AND COMPOSITIONS FOR MODIFYING A TARGETED LOCUS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18763265 | METHODS FOR MITIGATING DRUG TARGET INTERFERENCE IN AN ANTI-DRUG ANTIBODY (ADA) IMMUNOASSAY | HAQ, SHAFIQUL | 1678 | §103§112DP | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18721743 | NON-HUMAN ANIMALS COMPRISING HUMANIZED ACE2 AND TMPRSS LOCI | GRABER, JAMES J | 1631 | §101§102§103§112DP | Non-Final OA | — | Pending | Jun 19, 2024 |
| 18734482 | LOW AFFINITY FcyR DEFICIENT MICE | WILSON, MICHAEL C | 1638 | §112Other | Non-Final OA | — | Pending | Jun 05, 2024 |
| 18674399 | METHODS OF INCREASING STRENGTH AND FUNCTIONALITY WITH GDF8 INHIBITORS | HOWARD, ZACHARY C | 1674 | §112Other | Non-Final OA | — | Pending | May 24, 2024 |
| 18670684 | Chimeric Antigen Receptors with BCMA Specificity and Uses Thereof | BURKHART, MICHAEL D | 1638 | — | Non-Final OA | — | Pending | May 21, 2024 |
| 18670301 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | 1642 | §103§112Other | Non-Final OA | — | Pending | May 21, 2024 |
| 18670314 | STEROIDS AND ANTIBODY-CONJUGATES THEREOF | LU, CHENG | 1642 | §103DP | Non-Final OA | — | Pending | May 21, 2024 |
| 18669172 | Anti-CTLA-4 Antibodies and Uses Thereof | ROONEY, NORA MAUREEN | 1641 | §112DP | Non-Final OA | — | Pending | May 20, 2024 |
| 18659538 | SYSTEMS AND METHODS FOR REDUCING SAMPLE SIZES | ERICKSON, BENNETT S | 3683 | §101§103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18707263 | NON-HUMAN ANIMALS COMPRISING A MODIFIED CACNG1 LOCUS | MIANO, JOSEPH PAUL | 1631 | §101§102§103 | Non-Final OA | — | Pending | May 03, 2024 |
| 18647109 | METHODS FOR CHARACTERIZING LOW-ABUNDANCE HOST CELL PROTEINS | CHIN, CHRISTOPHER L | 1677 | §101 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18645694 | METHODS FOR SELECTING EXCIPIENTS AND FOR PREPARING HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS AND OTHER FORMULATIONS COMPRISING PROTEINS | SAOUD, CHRISTINE J | 1645 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18637055 | CONCENTRATION-DEPENDENT SELF-INTERACTION ASSAY | NGUYEN, NAM P | 1678 | §102§103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18634633 | SYSTEMS, METHODS, AND APPARATUSES FOR IMPROVED INSTRUMENT MONITORING AND ANALYTICS | MINCEY, JERMAINE A | 2159 | §101§102§103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18699454 | STEREOCILIN PROMOTERS AND USES THEREOF | MOLOYE, TITILAYO | 1632 | — | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18612039 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONIST | DONOGHUE, BRITTNEY ERIN | — | §102§112Other | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18610188 | COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABALATION FOR TREATING ALLERGY | CHANDRA, GYAN | 1674 | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18606302 | Proteomic Risk Score For Osteoarthritis (OA) | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18604573 | METHODS FOR OBTAINING ANTIBODY MOLECULES WITH HIGH AFFINITY | MARCSISIN, ELLEN JEAN | 1677 | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18592388 | ANTI-FEL D1 ANTIBODY FORMULATIONS | KIM, YUNSOO | 1641 | §103DP | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18589384 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | METCALF, MATTHEW CURRAN | 1647 | §102§103DP | Non-Final OA | — | Pending | Feb 27, 2024 |
| 18582159 | Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR) | KAPUSHOC, STEPHEN THOMAS | 1683 | §112DP | Non-Final OA | — | Pending | Feb 20, 2024 |
| 18436306 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | GONZALEZ, LUISALBERTO | 1624 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18432780 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | LI, RUIXIANG | 1674 | §112Other | Non-Final OA | — | Pending | Feb 05, 2024 |
| 18429572 | ASYMMETRICAL FLOW FIELD-FLOW FRACTIONATION WITH MASS SPECTROMETRY FOR BIOMACROMOLECULE ANALYSIS | XU, XIAOYUN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Feb 01, 2024 |
| 18421538 | CHARACTERIZATION OF SERINE-LYSINE CROSS-LINK IN ANTIBODY HIGH MOLECULAR WEIGHT SPECIES | COLE, HOUSTON DAVID | 1758 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 24, 2024 |
| 18543857 | HUMAN LAMBDA LIGHT CHAIN MICE | WILSON, MICHAEL C | 1638 | §112DP | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18535052 | Treatment Of Type 2 Diabetes With Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Agonists | PERSONS, JENNA L | 4100 | §112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18535105 | Treatment Of Prion Diseases | ZARA, JANE J | 1637 | §103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18528268 | METHODS TO CHARACTERIZING A FRAGMENT CRYSTALLIZABLE DOMAIN OF A BISPECIFIC ANTIBODY | RAMADAN, OMAR | 1678 | §102§103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18526599 | SYSTEMS AND METHODS FOR HIGH-THROUGHPUT PREDICTIONS | ELKINS, BLAKE HARRISON | — | §101§103§112 | Non-Final OA | — | Pending | Dec 01, 2023 |
| 18514880 | CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS | KIM, TAEYOON | 1631 | §103§112DP | Final Rejection | 35d | Pending | Nov 20, 2023 |
| 18512259 | DUAL-COLOR FLUORESCENCE CROSS-CORRELATION SPECTROSCOPY | SINES, BRIAN J | 1796 | §102§103§112 | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18510900 | Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) Inhibitors | HUDSON, AMY ROSE | 1636 | §103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18509030 | COMPOSITIONS AND METHODS FOR FIBROBLAST GROWTH FACTOR RECEPTOR 3-MEDIATED DELIVERY TO ASTROCYTES | HUYNH, PHUONG N | 1641 | §112DP | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18389375 | METHODS FOR DETECTING AND EVALUATING VIRUSES AND VIRUS-LIKE PARTICLES | WHITE, DENNIS MICHAEL | 2877 | §102§103 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18509136 | ANTI-FGFR3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS AND METHODS OF USE THEREOF | BENAVIDES, JENNIFER ANN | 1675 | §112Other | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18501865 | CALCIUM VOLTAGE-GATED CHANNEL AUXILIARY SUBUNIT GAMMA 1 (CACNG1) BINDING PROTEINS AND CACNG1-MEDIATED DELIVERY TO SKELETAL MUSCLE | HALVORSON, MARK | 1646 | §112 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18497352 | METHODS OF TREATING CANCER WITH A COMBINATION OF ADOPTIVE CELL THERAPY AND A TARGETED IMMUNOCYTOKINE | STONEBRAKER, ALYSSA RAE | 1642 | §103§112DP | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18495477 | ANTI-ACVRI ANTIBODIES AND THEIR USE IN THE TREATMENT OF TRAUMA-INDUCED HETEROTOPIC OSSIFICATION | MELCHIOR, JAMES RYLAND | 1644 | §112 | Non-Final OA | — | Pending | Oct 26, 2023 |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | ZAHORIK, AMANDA MARY | 1636 | §112 | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18478273 | CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES | WRIGHT, ERIC BRANDON | 1632 | §112 | Final Rejection | — | Pending | Sep 29, 2023 |
| 18374492 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | BUNKER, AMY M | 1684 | §102§112DP | Final Rejection | — | Pending | Sep 28, 2023 |
| 18472847 | GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF HUMAN CELLULAR IMMUNE SYSTEM | MOORE, JOHN DAVID | 1638 | §103 | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18472160 | METHODS OF TREATING OBESITY, DIABETES, AND LIVER DYSFUNCTION | PRIEST, JESSICA MARIE | 1642 | §102§112DP | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18367444 | AN AQUEOUS PHARMACEUTICAL FORMULATION INCLUDING A VEGF RECEPTOR FUSION PROTEIN | LOCKARD, JON MCCLELLAND | 1647 | §112 | Non-Final OA | — | Pending | Sep 12, 2023 |
| 18244577 | Treatment Of Endometriosis With R-Spondin 3 (RSPO3) Inhibitors | TATGE, LEXUS MARC | 1637 | §101§112 | Final Rejection | 22d | Pending | Sep 11, 2023 |
| 18549621 | WORKFLOW TO ASSIGN PUTATIVE SOURCE TO DE NOVO PEPTIDE SEQUENCE | SCHULTZHAUS, JANNA NICOLE | 1685 | §101§103§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18459221 | METHODS OF TREATING NON-SMALL CELL LUNG CANCER USING MESENCHYMAL EPITHELIAL TRANSITION FACTOR (MET)-TARGETED AGENTS | HINES, JANA A | 1645 | §103 | Final Rejection | — | Pending | Aug 31, 2023 |
| 18459091 | CRISPR/CAS DROPOUT SCREENING PLATFORM TO REVEAL GENETIC VULNERABILITIES ASSOCIATED WITH TAU AGGREGATION | CHONG, KIMBERLY | 1636 | §112 | Non-Final OA | — | Pending | Aug 31, 2023 |
| 18547192 | METHODS OF TREATING LUNG CANCER BY ADMINISTERING A PD-1 INHIBITOR | HOPKINS, SAMANTHA LAKE | 1641 | §102Other | Final Rejection | 61d | Pending | Aug 21, 2023 |
| 18452452 | INTERFERON RECEPTOR AGONISTS AND USES THEREOF | JOHNSON, TIRONE DEREK | 1675 | §103§112Other | Non-Final OA | 34d | Pending | Aug 18, 2023 |
| 18547150 | METHOD FOR DIAGNOSING AND TREATING PARTIAL LIPODYSTROPHY | TOTH, KAREN E | 3791 | §101§102§103§112 | Non-Final OA | 83d | Pending | Aug 18, 2023 |
| 18234101 | Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGF | KRIANGCHAIVECH, KETTIP | 1686 | §101§112 | Non-Final OA | — | Pending | Aug 15, 2023 |
| 18229117 | Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies | JOHANSEN, PETER N. | 1644 | §102§103DP | Final Rejection | — | Pending | Aug 01, 2023 |
| 18355108 | Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof | SCHWECHTER, BRANDON ROSS | 1674 | §112 | Final Rejection | 34d | Pending | Jul 19, 2023 |
| 18223434 | VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME | CONNORS, ALEXANDRA F | 1634 | §103§112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 18221934 | ISOELECTRIC FOCUSING-BASED ENRICHMENT OF CHARGE VARIANT SPECIES | FRITCHMAN, REBECCA M | 1758 | §103 | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18350867 | MILD ACID IMMUNOASSAYS FOR DETECTION OF ANALYTES | COUNTS, GARY W | 1678 | §103§112 | Final Rejection | — | Pending | Jul 12, 2023 |
| 18344494 | AUTO-INJECTOR AND RELATED METHODS OF USE | STIGELL, THEODORE J | 3783 | §102 | Final Rejection | — | Pending | Jun 29, 2023 |
| 18340917 | NON-HUMAN ANIMALS HAVING A HUMANIZED CLEC9A GENE | CANDELARIA, JULIANA IRENE | 1634 | §112 | Final Rejection | 12d | Pending | Jun 26, 2023 |
| 18324380 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112 | Non-Final OA | — | Pending | May 26, 2023 |
| 18197579 | BIOANALYSIS OF THERAPEUTIC ANTIBODIES AND RELATED PRODUCTS USING IMMUNOPRECIPITATION AND NATIVE SEC-PCD-MS DETECTION | SPANGLER, JOSEPH RANKIN | 1656 | §103§112Other | Non-Final OA | — | Pending | May 15, 2023 |
| 18317241 | ANTI-LAG3 ANTIBODIES AND USES THEREOF | OUSPENSKI, ILIA I | 1644 | DP | Final Rejection | 52d overdue | Pending | May 15, 2023 |
| 18313745 | METHODS AND SYSTEMS FOR CHROMATOGRAPHY DATA ANALYSIS | TCHATCHOUANG, CARL F.R. | 2858 | DP | Non-Final OA | — | Pending | May 08, 2023 |
| 18310921 | METHODS FOR REDUCING LIPASE ACTIVITY | MCKNIGHT, CIARA A | 1656 | §103Other | Final Rejection | 54d | Pending | May 02, 2023 |
| 18306737 | Transcriptome Analysis For Treating Inflammation | SMITH, EMILIE ALINE | 1686 | §103§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18133288 | COMPOSITIONS AND METHODS FOR UNIVERSAL TUMOR CELL KILLING | STONEBRAKER, ALYSSA RAE | 1642 | §103§112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18130980 | COMPOSITIONS AND METHODS FOR TREATING POLYMYALGIA RHEUMATICA BY ADMINISTERING AN IL-6R ANTAGONIST | HOWARD, ZACHARY C | 1674 | §102§103§112 | Non-Final OA | 127d overdue | Pending | Apr 05, 2023 |
| 18129923 | G PROTEIN-COUPLED RECEPTOR 75 (GPR75) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | MEYERING, SHABANA SHABBEER | 1635 | §102§103 | Non-Final OA | 62d | Pending | Apr 03, 2023 |
| 18247226 | COMBINATION OF ANTIBODIES FOR TREATING CANCER WITH REDUCED CYTOKINE RELEASE SYNDROME | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Final Rejection | — | Pending | Mar 29, 2023 |
| 18182323 | ANTI-GLP1R ANTIBODY-TETHERED DRUG CONJUGATES COMPRISING GLP1 PEPTIDOMIMETICS AND USES THEREOF | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 27d | Pending | Mar 11, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18175852 | MANUFACTURING PROCESS FOR HIGH TITER ANTIBODY | GRIZER, CASSANDRA SENN | 1672 | §103§112DP | Non-Final OA | — | Pending | Feb 28, 2023 |
| 18115285 | BIOREACTOR FOR ANTIBODY PRODUCTION | CANDELARIA, JULIANA IRENE | 1634 | §103§112 | Final Rejection | 21d | Pending | Feb 28, 2023 |
| 18115354 | CELL CULTURE METHODS FOR ANTIBODY PRODUCTION | MCKNIGHT, CIARA A | 1656 | §103§112DP | Final Rejection | — | Pending | Feb 28, 2023 |
| 18114057 | Dosing Regimens for Mitigation of Cytokine Release Syndrome | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | — | Pending | Feb 24, 2023 |
| 18042441 | METHODS OF TREATING CANCER BY ADMINISTERING A PD-1 INHIBITOR | AEDER, SEAN E | 1642 | §103 | Non-Final OA | 42d | Pending | Feb 21, 2023 |
| 18105772 | Stabilized Formulations Containing Anti-IL-33 Antibodies | KIM, YUNSOO | 1641 | §103 | Non-Final OA | — | Pending | Feb 03, 2023 |
| 18159445 | DRUG DELIVERY DEVICE SAFETY SYSTEM | TRINH, HONG-VAN N | 3783 | §103 | Non-Final OA | — | Pending | Jan 25, 2023 |
| 18095467 | PROTEIN-DRUG CONJUGATES COMPRISING CAMPTOTHECIN ANALOGS AND METHODS OF USE THEREOF | CANELLA, KAREN A | 1643 | §103§112 | Final Rejection | 20d | Pending | Jan 10, 2023 |
| 18069110 | OFF-TARGET PREDICTION METHOD FOR ANTIGEN-RECOGNITION MOLECULES BINDING TO MHC-PEPTIDE TARGETS | LEVERETT, MARY CHANG | 1687 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18059719 | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Score Relating To Response To A Therapeutic Agent | GODDARD, LAURA B | 1642 | §101§103§112 | Non-Final OA | — | Pending | Nov 29, 2022 |
| 18057298 | Methods Of Treating Headaches And Migraines With Sodium Voltage-Gated Channel Alpha Subunit 11 (SCN11A) Inhibitors | TATGE, LEXUS MARC | 1637 | §101§112 | Final Rejection | — | Pending | Nov 21, 2022 |
| 18055895 | AUTO-INJECTOR AND RELATED METHODS OF USE | GONZALEZ, LEI NMN | 3783 | §103 | Non-Final OA | 39d | Pending | Nov 16, 2022 |
| 17920069 | NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE | DHAR, MATASHA | 1632 | §103 | Non-Final OA | 46d overdue | Pending | Oct 20, 2022 |
| 17936715 | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | ANGELL, JON E | 1637 | §112 | Final Rejection | 13d | Pending | Sep 29, 2022 |
| 17954999 | ASSAYS TO QUANTITATE DRUG AND TARGET CONCENTRATIONS | EVANS, CHRISTOPHER RYAN | 1677 | §102§103§112 | Final Rejection | 4d overdue | Pending | Sep 28, 2022 |
| 17948382 | METHODS OF CONTROLLING ANTIBODY HETEROGENEITY | O'NEILL, MARISOL ANN | 1633 | §102§103 | Non-Final OA | — | Pending | Sep 20, 2022 |
| 17933148 | ANTI-C5 ANTIBODIES AND USES THEREOF | ALAWADI, SARAH | 1619 | §112 | Non-Final OA | — | Pending | Sep 19, 2022 |
| 17930471 | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS | XU, XIAOYUN | 1797 | §103 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17821806 | Treatment Of Inflammatory Diseases With RAS Protein Activator Like 3 (RASAL3) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Non-Final OA | — | Pending | Aug 24, 2022 |
| 17887565 | IL27 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | DONOGHUE, BRITTNEY ERIN | 1675 | §103 | Non-Final OA | 15d overdue | Pending | Aug 15, 2022 |
| 17885805 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 1653 | §101§103§112 | Final Rejection | 13d | Pending | Aug 11, 2022 |
| 17870368 | NATIVE MICROFLUIDIC CE-MS ANALYSIS OF ANTIBODY CHARGE HETEROGENEITY | XU, XIAOYUN | 1797 | §103Other | Non-Final OA | 55d | Pending | Jul 21, 2022 |
| 17813100 | COMBINATION OF CHECKPOINT INHIBITORS AND AN ONCOLYTIC VIRUS FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103 | Final Rejection | — | Pending | Jul 18, 2022 |
| 17863303 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | WHITE, ASHLEY TAYLOR | 1653 | §101§103DP | Non-Final OA | — | Pending | Jul 12, 2022 |
| 17862240 | Methods for Viral Particle Characterization Using Two-Dimensional Liquid Chromatography-Mass Spectrometry | ZOU, NIANXIANG | 1671 | §103§112 | Final Rejection | 20d | Pending | Jul 11, 2022 |
| 17851845 | NMR METHODS FOR ANTIBODY HIGHER ORDER STRUCTURE COMPARABILITY | BERKELEY, EMILY R | 1796 | §101§102§103 | Non-Final OA | — | Pending | Jun 28, 2022 |
| 17782508 | VEGF MINI-TRAPS AND METHOD OF USE THEREOF | DABKOWSKI, ERINNE R | 1654 | §103§112DP | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17735510 | MULTISPECIFIC FGF21 RECEPTOR AGONISTS AND THEIR USES | SAOUD, CHRISTINE J | 1600 | §112 | Non-Final OA | — | Pending | May 03, 2022 |
| 17734688 | BIOCHEMICAL ASSAYS FOR THERAPEUTIC PROTEINS | HALVORSON, MARK | 1646 | §102 | Final Rejection | — | Pending | May 02, 2022 |
| 17684674 | SYSTEMS AND METHODS FOR QUANTIFYING AND MODIFYING PROTEIN VISCOSITY | XU, XIAOYUN | 1797 | §103 | Non-Final OA | 31d overdue | Pending | Mar 02, 2022 |
| 17683468 | Treatment Of Liver Disease With Ring Finger Protein 213 (RNF213) Inhibitors | VYAS, KEYUR ANILKUMAR | 1637 | §112 | Final Rejection | — | Pending | Mar 01, 2022 |
| 17591355 | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof | ZEMAN, MARY K | 1686 | §101§103§112DP | Non-Final OA | — | Pending | Feb 02, 2022 |
| 17584642 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | HAMA, JOANNE | 1647 | §112Other | Final Rejection | — | Pending | Jan 26, 2022 |
| 17579185 | RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN MICE | WEHBE, ANNE MARIE SABRINA | 1634 | Other | Non-Final OA | — | Pending | Jan 19, 2022 |
| 17615732 | MODIFIED DOSAGE OF SUBCUTANEOUS TOCILIZUMAB FOR RHEUMATOID ARTHRITIS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Dec 01, 2021 |
| 17612669 | MODIFIED VIRAL PARTICLES AND USES THEREOF | RIGA, MICHAEL ANGELO | 1634 | §102§103§112 | Non-Final OA | — | Pending | Nov 19, 2021 |
| 17611073 | COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS FOR ENHANCED EFFICACY IN TREATING CANCER | WU, JULIE ZHEN QIN | 1643 | §103 | Final Rejection | 3d overdue | Pending | Nov 12, 2021 |
| 17476078 | Use of LEPR Agonists for Pain | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Sep 15, 2021 |
| 17469308 | METHOD FOR DETECTING HOST CELL PROTEINS IN THERAPEUTIC ANTIBODIES BY COMBINING TRYPSIN DIGESTION, CHROMATOGRAPHY GRADIENTS, AND BOXCAR MASS SPECTROMETRY | SWIFT, CANDICE LEE | 1657 | §103§112 | Final Rejection | — | Pending | Sep 08, 2021 |
| 17433887 | ADENO-ASSOCIATED VIRUS VECTORS FOR THE DELIVERY OF THERAPEUTICS | LEONARD, ARTHUR S | 1631 | §103§112 | Non-Final OA | 6d | Pending | Aug 25, 2021 |
| 17356497 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | CANELLA, KAREN A | 1643 | §102§103§112 | Final Rejection | 8d | Pending | Jun 23, 2021 |
| 17236998 | METHODS AND SYSTEMS FOR ANALYSIS OF RECEPTOR INTERACTION | SABOUR, GHAZAL | 1686 | §103 | Final Rejection | 4d overdue | Pending | Apr 21, 2021 |
| 17204253 | NON-HUMAN ANIMALS THAT SELECT FOR LIGHT CHAIN VARIABLE REGIONS THAT BIND ANTIGEN | NGUYEN, NAM P | 1678 | §102§112 | Final Rejection | 26d | Pending | Mar 17, 2021 |
| 17203566 | TARGET INTERFERENCE MITIGATION IN ANTI-DRUG ANTIBODY ASSAY | HAQ, SHAFIQUL | 1678 | §112 | Final Rejection | — | Pending | Mar 16, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
| 17268719 | METHOD AND CHROMATOGRAPHY SYSTEM FOR DETERMINING AMOUNT AND PURITY OF A MULTIMERIC PROTEIN | GERMAIN, ADAM ADRIEN | 1777 | §103 | Final Rejection | — | Pending | Feb 16, 2021 |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | WILSON, MICHAEL C | 1638 | §112 | Final Rejection | — | Pending | Dec 07, 2020 |
| 17112198 | METHODS FOR TREATING COPD BY ADMINISTERING AN IL-33 ANTAGONIST | BENAVIDES, JENNIFER ANN | 1675 | §103 | Non-Final OA | — | Pending | Dec 04, 2020 |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 4d overdue | Pending | Sep 24, 2020 |
| 16993434 | HIGH CONCENTRATION ANTI-C5 FORMULATIONS | ESSEX, LAURA ANN | 1675 | §103§112 | Non-Final OA | 53d | Pending | Aug 14, 2020 |
| 16984531 | METABOLICALLY OPTIMIZED CELL CULTURE | SCHUBERG, LAURA J | 1631 | §103Other | Non-Final OA | — | Pending | Aug 04, 2020 |
| 16880736 | METHODS FOR IDENTIFYING AND QUANTITATING HOST CELL PROTEIN | MARCSISIN, ELLEN JEAN | 1677 | §103 | Non-Final OA | — | AI Ready | May 21, 2020 |
| 16863800 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST | JOHANSEN, PETER N. | 1644 | §103DP | Final Rejection | — | Pending | Apr 30, 2020 |
| 16644650 | Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) Variants And Uses Thereof | SITTON, JEHANNE SOUAYA | 1682 | §103§112 | Non-Final OA | — | Pending | Mar 05, 2020 |
| 16625207 | Tropism-Modified Recombinant Viral Particles and Uses Thereof for the Targeted Introduction of Genetic Material into Human Cells | GROOMS, TIFFANY NICOLE | 1637 | §103§112 | Non-Final OA | — | Pending | Dec 20, 2019 |
| 16278611 | GAN-CNN FOR MHC PEPTIDE BINDING PREDICTION | BICKHAM, DAWN MARIE | 1685 | §101§103§112 | Final Rejection | — | Pending | Feb 18, 2019 |
| 15766586 | STABLE PROTEIN COMPOSITIONS | SAEED, ALI S | 1616 | §103§112 | Non-Final OA | 83d | Pending | Apr 06, 2018 |
| 15034531 | COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME | PAK, MICHAEL D | 1674 | §103§112DP | Non-Final OA | — | Pending | May 04, 2016 |
| 15130780 | METABOLICALLY OPTIMIZED CELL CULTURE | SCHUBERG, LAURA J | 1631 | §103Other | Non-Final OA | — | Pending | Apr 15, 2016 |